Navigating the procurement of high-purity Follistatin variants requires rigorous verification of analytical documentation, lot consistency, and manufacturing compliance. PX1 Research delivers laboratory-grade research compounds designed exclusively for in vitro and preclinical experimental applications.
Navigating the procurement of high-purity Follistatin variants requires rigorous verification of analytical documentation, lot consistency, and manufacturing compliance. PX1 Research delivers laboratory-grade research compounds designed exclusively for in vitro and preclinical experimental applications.
Researchers seeking to bestellen follistatine peptide online must prioritize analytical transparency, supplier validation, and lot-specific verification over commercial claims. Laboratory-grade Follistatin variants should always be accompanied by third-party High-Performance Liquid Chromatography (HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS) documentation to confirm chemical identity and sequence purity.
When purchasing recombinant peptides for experimental protocols, investigators must verify that the material is synthesized under stringent quality control standards. In vitro assays and animal models require uncompromised sequence fidelity to prevent non-specific cellular signaling or aberrant binding activity. PX1 Research supplies validated research compounds produced in USA-based facilities, ensuring that every batch meets defined analytical benchmarks prior to distribution.
To ensure reproducible outcomes across longitudinal studies, research institutions must establish strict criteria for candidate peptide procurement. Key quality indicators include verified purity exceeding 98%, low endotoxin levels quantified by Limulus Amebocyte Lysate (LAL) testing, and stable lyophilization profiles that preserve tertiary structure during transport and storage.
Follistatin (FS) is an autocrine single-chain glycoprotein expressed in human and mammalian tissues, encoded by the FST gene. Alternative splicing of precursor messenger RNA produces distinct isoforms, primarily Follistatin-288 (FS-288), Follistatin-315 (FS-315), and the domain-truncated Follistatin-344 (FS-344). These structural variants exhibit distinct tissue affinity, systemic clearance rates, and biological half-lives in experimental systems.
The primary structural characteristic of Follistatin is its high-affinity binding interaction with members of the Transforming Growth Factor-beta (TGF-β) superfamily. Structurally, the molecule contains an N-terminal domain followed by three conserved Follistatin domains (FS1, FS2, and FS3). The basic residues situated within the FS1 and FS2 domains facilitate high-affinity electrostatic interactions with cell-surface heparin sulfate proteoglycans, particularly in short-chain isoforms such as FS-288.
In contrast, extended isoforms such as Follistatin-315 possess a C-terminal extension that masks the core heparin-binding region, allowing the peptide to circulate more freely in systemic circulation during animal studies. Understanding these structural variations is critical when selecting specific sequences from our catalog of research peptides for targeted organ or cellular models.
The principal bioactivity of Follistatin revolves around its potent neutralizing capability against Activin A, Activin B, and Myostatin (also designated as Growth Differentiation Factor-8 or GDF-8). In vitro binding kinetics demonstrate that Follistatin forms an irreversible, non-covalent stoichiometric complex with Activin dimers, effectively blocking their ability to engage cell-surface Activin type II receptors (ActRIIA and ActRIIB).
By occupying the ligand-binding domain of ActRIIB, Follistatin prevents the downstream recruitment and phosphorylation of intracellular signaling transducers, specifically the SMAD2 and SMAD3 complex. In normal cellular homeostasis, activated SMAD2/3 translocates to the nucleus to induce transcription of gene targets that restrict cellular proliferation and promote catabolic pathways.
Preclinical studies suggest that suppressing local SMAD2/3 phosphorylation via recombinant Follistatin administration shifts cellular signaling toward anabolic pathways. Investigations into myostatin inhibition mechanisms indicate that this disruption elevates expression of MyoD and Myogenin, crucial transcription factors involved in satellite cell activation and muscle progenitor differentiation.
In vitro data indicate that incubating primary myoblast cultures with recombinant Follistatin accelerates myotube fusion and increases total protein synthesis rates. Cell culture models demonstrate enhanced expression of heavy-chain myosin and diminished nuclear translocation of phospho-SMAD2 following treatment, confirming efficient signaling blockage at the receptor surface.
In vivo investigations utilizing rodent models of muscular dystrophy and disuse atrophy have evaluated the systemic and localized effects of elevated Follistatin levels. Transgenic mouse models overexpressing Follistatin display marked increases in skeletal muscle mass, cross-sectional myofiber area, and peak isometric force production without proportional organomegaly.
Furthermore, preclinical research highlights potential cross-talk between Follistatin signaling and adipose tissue metabolism. Rodent studies demonstrate that suppression of TGF-β family ligands by Follistatin leads to increased brown adipose tissue (BAT) activation and enhanced thermogenic gene expression, providing valuable frameworks for metabolic research protocols.
When designing protocols targeting the GDF-8/ActRIIB axis, investigators often compare Follistatin against other targeted agents, such as soluble ActRIIB-Fc decoy receptors and specialized growth factor variants like IGF-1 LR3. While soluble ActRIIB-Fc receptors bind circulating GDF-8 and Activin with high affinity, their broad binding spectrum can cross-react with BMP-9 and BMP-10, potentially altering vascular homeostasis in animal models.
Follistatin isoforms, specifically Follistatin-344, present a distinct pharmacological profile by predominantly targeting local Activin A and Myostatin while maintaining unique heparin-binding characteristics. Compared to direct anabolic peptides like IGF-1 DES, which directly stimulate the RTK/Akt/mTOR axis to induce protein synthesis, Follistatin acts indirectly by removing negative transcriptional regulators.
A comparison of candidate compounds highlights key mechanistic differences across this target class:
- **Follistatin-344:** Truncated precursor isoform studied for localized biological action and rapid tissue binding. - **Follistatin-315:** Circulating systemic isoform exhibiting reduced heparin affinity and prolonged serum presence in vivo. - **ActRIIB-Fc:** Extracellular domain fusion protein offering broad ligand sequestration across the TGF-β superfamily. - **IGF-1 LR3:** Synthetic insulin-like growth factor analog providing direct activation of the IGF-1R signaling cascade.
Selecting the appropriate compound depends entirely on whether the experimental protocol aims to evaluate direct receptor activation or local regulatory inhibition. For detailed comparative data, consult our technical guide on follistatin isoforms compared.
Proper handling and reconstitution of lyophilized Follistatin are critical to maintaining protein integrity and preventing irreversible aggregation. Because Follistatin is a delicate complex glycoprotein containing multiple intramolecular disulfide bonds, exposure to mechanical agitation or improper solvents can result in denaturating or loss of tertiary structure.
Prior to reconstitution, vials should be equilibrated to room temperature to prevent condensation within the container. Centrifuge the vial briefly at low speed (1000–2000 × g) to collect the lyophilized cake at the bottom of the vessel. Reconstitution should be performed using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile PBS (phosphate-buffered saline, pH 7.4) depending on the intended assay parameters.
Gently inject the solvent along the inner glass wall of the vial rather than applying direct force onto the lyophilized pellet. Allow the cake to dissolve naturally over 5–10 minutes, followed by gentle side-to-side swirling. Never vortex reconstituted peptide solutions. For long-term storage of aliquots, incorporate a carrier protein such as 0.1% Bovine Serum Albumin (BSA) or Human Serum Albumin (HSA) to minimize surface adsorption to plastic microtubes.
Securing authentic, high-purity peptides requires meticulous validation of every production lot. Laboratory buyers must insist on receiving independent Certificate of Analysis (COA) documentation generated by an accredited ISO 17025 third-party laboratory prior to accepting shipment.
At PX1 Research, every lot of Follistatin undergoes rigorous analytical characterization:
1. **Reverse-Phase HPLC (RP-HPLC):** Verifies chemical purity by separating the target sequence from truncated synthesis byproducts or degradation fragments. Purity thresholds must consistently exceed 98.0% peak area integration. 2. **Electrospray Ionization Mass Spectrometry (ESI-MS):** Confirms exact molecular weight and sequence identity, ensuring no amino acid substitutions or post-translational mis-foldings have occurred. 3. **Endotoxin Quantification (LAL Assay):** Measures bacterial endotoxin levels to ensure values remain below <0.01 EU/μg, preventing non-specific immune activation in sensitive cell cultures and animal models. 4. **Sterility and Bioburden Testing:** Guarantees freedom from viable microbial contamination under strict culture conditions.
Researchers evaluating bulk supply for large-scale projects can access comprehensive documentation through our dedicated wholesale laboratory portal.
Lyophilized Follistatin exhibits optimal chemical stability when stored at controlled sub-zero temperatures. Upon receipt, desiccated vials should be immediately transferred to a freezer maintained at -20°C or -80°C. Under these conditions, the lyophilized peptide remains stable for up to 24 months without significant loss of bioactivity or chemical degradation.
Once reconstituted in sterile aqueous buffer, the solution's stability drops significantly. Liquid aliquots stored at 2°C to 8°C should be utilized within 7 to 14 days. For extended experimental timelines, reconstituted solutions must be divided into single-use working aliquots and stored at -80°C to avoid repeated freeze-thaw cycles.
Repeated freezing and thawing causes ice crystal formation that disrupts hydrogen bonding, leading to severe protein denaturation and irreversible precipitation. Always store aliquots in low-binding polypropylene tubes to prevent losses attributable to container surface absorption.
When decision-makers evaluate options to bestellen follistatine peptide online, supplier infrastructure and quality control standards represent the primary operational variables. Purchasing from unverified overseas vendors carries significant risk of variable purity, sequence errors, high endotoxin contamination, and erratic shipping timelines.
PX1 Research operates strictly within USA-based manufacturing frameworks, utilizing GMP-compliant synthesis processes and state-of-the-art analytical equipment. Every batch undergoes rigorous lot-specific analysis to guarantee structural purity and physiological safety for cellular models.
Furthermore, supply chain integrity relies on efficient, temperature-monitored logistics. Products dispatched from PX1 Research originate directly from our distribution hubs in California and Arizona, offering same-day dispatch for orders placed before standard cutoff times, ensuring your laboratory maintains continuity without supply chain interruptions.
What is the primary application of Follistatin in laboratory research?
Follistatin is supplied exclusively as a research compound for in vitro assays and preclinical animal models. It is utilized to study the TGF-β signaling pathway, specific interactions with Activin A/B, and mechanisms governing myostatin inhibition and muscle stem cell dynamics.
How does PX1 Research verify the purity of its Follistatin peptide?
Every lot of Follistatin undergoes comprehensive third-party testing at an accredited ISO 17025 laboratory. Testing includes Reverse-Phase HPLC to confirm >98% purity, ESI-Mass Spectrometry to verify exact molecular weight, and LAL assays to ensure endotoxin levels remain below 0.01 EU/μg.
What is the difference between Follistatin-315 and Follistatin-344?
Follistatin-315 is the primary circulating isoform in vivo featuring a C-terminal sequence that neutralizes heparin-binding, permitting systemic distribution. Follistatin-344 is a precursor isoform frequently studied for localized tissue binding due to its distinct structural properties.
How should lyophilized Follistatin be stored upon delivery?
Lyophilized Follistatin should be stored at -20°C or -80°C in a dry, dark environment upon receipt. Properly stored lyophilized powder remains stable for up to 24 months.
What solvent should be used to reconstitute Follistatin for in vitro assays?
Reconstitution is typically performed using sterile Bacteriostatic Water or sterile phosphate-buffered saline (PBS, pH 7.4). For long-term aliquot storage, adding 0.1% carrier protein (such as BSA) helps prevent peptide adhesion to plastic tube surfaces.
Can reconstituted Follistatin undergo multiple freeze-thaw cycles?
No. Repeated freeze-thaw cycles cause mechanical shearing and denaturation of the tertiary peptide structure. Reconstituted solutions should be divided into single-use micro-aliquots and stored at -80°C.
Where are PX1 Research peptides manufactured and shipped from?
All PX1 Research compounds are manufactured in USA-based facilities adherence to strict quality control standards. Orders ship directly from our centralized distribution facilities in California and Arizona.
What are the endotoxin limits enforced for PX1 Research peptides?
PX1 Research mandates strict endotoxin thresholds, guaranteeing levels below <0.01 EU/μg via Chromogenic LAL testing to prevent unexpected cellular toxicity or immune activation in experimental protocols.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.